72 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 OFICHEM In a climate of increased regulatory hurdles and disruption across global supply chains, Ofichem is marking its 50th anniversary with a shift toward wider expansion, through targeted acquisitions, reinforcing its end-to-end development model, and prioritising valued partnerships. At last year’s CPHI in Frankfurt, the manufacturer celebrated half a century of API development, discussing recent purchases of the Avivia formulation business in Nijmegen, Netherlands and a former Recipharm facility in Uppsala, Sweden in moves that build Ofichem’s technological capabilities and geographical reach. Speaking to 24/7 BIOPHARMA, business development executive Marinus Bouma said the acquisitions, “represented possibilities in pre-clinical chemistry, analytical services, all non-GMP. So the opportunities are limitless there with very short lead times.” “Our end-to-end service offering supports customers in shorting development timelines, bringing products fast to market and make use of Ofichem’s technical problem solver skills… We carry out formulation development, research support and traditional CMO business.” “The takeaway for us is getting visibility, expanding the network, offering additional service solutions to existing and new customers … as part of the Life Science industry.” Strengthening supply chains Founded in 1975, Ofichem has grown from a small Dutch API producer into a multi-facility group spanning the Netherlands and Sweden. Over time, Ofichem’s API operations have integrated a sourcing arm that stockpiles Asian-made APIs to stabilise customer supply chains. The company recently underscored its position within a broader shift back toward European manufacturing, noting that tightening regulation, supply-chain reshoring and renewed scrutiny of Asian sourcing have accelerated demand for EU-based CDMOs. They also previously commented on the industry’s push for higher quality standards and greater supplychain robustness that plays directly to the strengths of mid-sized European producers with established analytical capabilities and long-standing regulatory experience.1
RkJQdWJsaXNoZXIy MjY2OTA4MA==